65 Shares in Eli Lilly and Company (NYSE:LLY) Purchased by West Financial Advisors LLC

West Financial Advisors LLC bought a new stake in shares of Eli Lilly and Company (NYSE:LLY) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 65 shares of the company’s stock, valued at approximately $58,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Lynx Investment Advisory acquired a new stake in Eli Lilly and Company in the 2nd quarter valued at about $32,000. LGT Financial Advisors LLC purchased a new position in Eli Lilly and Company during the second quarter worth approximately $36,000. Redmont Wealth Advisors LLC acquired a new position in Eli Lilly and Company during the first quarter worth $40,000. Morton Brown Family Wealth LLC grew its holdings in Eli Lilly and Company by 45.5% in the 2nd quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock valued at $41,000 after buying an additional 15 shares in the last quarter. Finally, Richardson Financial Services Inc. acquired a new stake in shares of Eli Lilly and Company in the 4th quarter worth $43,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

LLY stock opened at $919.91 on Thursday. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. The company has a market capitalization of $874.29 billion, a P/E ratio of 135.48, a PEG ratio of 2.78 and a beta of 0.42. The business has a 50 day simple moving average of $904.41 and a 200-day simple moving average of $850.31. Eli Lilly and Company has a twelve month low of $547.61 and a twelve month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. The firm had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. As a group, equities analysts anticipate that Eli Lilly and Company will post 16.49 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $1,025.00 price objective on shares of Eli Lilly and Company in a report on Thursday, October 3rd. Berenberg Bank lifted their price target on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Jefferies Financial Group increased their price objective on Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research report on Monday, June 24th. Guggenheim lifted their target price on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Finally, BMO Capital Markets increased their price target on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $977.35.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.